A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

NCT05519865 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Tucidinostat
DRUG: Tislelizumab

Sponsor

Chipscreen Biosciences, Ltd.